Mild Cognitive Impairment – Epidemiology – Asia Pacific
Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model when the future effects of exposure can be reasonably quantified. The Factors table summarizes all of the factors that were considered for inclusion in our model.
Table of contents
- Mild Cognitive Impairment - Epidemiology - Asia Pacific
- Introduction
- Key Findings
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Related Market Assessment Reports
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
